BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schattenberg JM. Reading the stars for hepatic fibrosis or how to predict the severity of liver disease in patients with NASH. Liver Int 2019;39:812-4. [PMID: 31020772 DOI: 10.1111/liv.13999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Labenz C, Toenges G, Zheng M, Ding D, Myers RP, Galle PR, Armandi A, Ampuero J, Gómez MR, Bugianesi E, Anstee QM, Schattenberg JM. Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2021.12.011] [Reference Citation Analysis]
2 Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K, Leeming DJ, Karsdal MA, Galle PR, Simon P, Schattenberg JM. Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol Ther 2019;50:930-9. [PMID: 31342533 DOI: 10.1111/apt.15427] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
3 Luo N, Li J, Chen Y, Xu Y, Wei Y, Lu J, Dong R. Hepatic stellate cell reprogramming via exosome-mediated CRISPR/dCas9-VP64 delivery. Drug Deliv 2021;28:10-8. [PMID: 33336604 DOI: 10.1080/10717544.2020.1850917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Schattenberg JM, Labenz C, Wörns MA, Menge P, Weinmann A, Galle PR, Sprinzl MF. Patterns of liver injury in COVID-19 - a German case series. United European Gastroenterol J 2020;8:814-9. [PMID: 32588791 DOI: 10.1177/2050640620931657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]